In the UK research into the affects on pregnancy are limited and I wondered if anyone could advise me on wether I should continue treatment during my pregnancy?
I think only you and your doctor can make a decision like that. For us to interfere, I fear all you will get is advice based on personal ethics and morality. If you can, visit a university library (that has a medical school) and try searching the Lancet or other medical journals to see if anyone has studied this. You may only need to quit treatment (if that is how you are leaning) for part of your pregnancy.
This is what the FDA has to say (which is probably exactly what you have read): https://www.drugs.com/pro/entyvio-injection.html
"USE IN SPECIFIC POPULATIONS
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ENTYVIO during pregnancy. Information about the registry can be obtained by calling 1-877-TAKEDA7 (1-877-825-3327).
Pregnancy Category B:
There are no studies with ENTYVIO in pregnant women. No fetal harm was observed in animal reproduction studies with intravenous administration of vedolizumab to rabbits and monkeys at dose levels 20 times the recommended human dosage. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the benefits to the mother outweigh the risk to the unborn child.
Any adverse pregnancy effect from ENTYVIO would likely be greater during the second and third trimesters of pregnancy. Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester.
A reproduction study has been performed in pregnant rabbits at single intravenous doses up to 100 mg/kg administered on gestation Day 7 (about 20 times the recommended human dosage) and has revealed no evidence of impaired fertility or harm to the fetus due to vedolizumab. A pre- and post-natal development study in monkeys showed no evidence of any adverse effect on pre- and post-natal development at intravenous doses up to 100 mg/kg (about 20 times the recommended human dosage)."
- Vedolizumab Information for Consumers
- Vedolizumab Information for Healthcare Professionals (includes dosage details)
- Side Effects of Vedolizumab (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 5 Oct 2009 • 7 answers
Posted 6 Feb 2010 • 2 answers
Posted 2 Oct 2011 • 3 answers
Posted 22 Sep 2013 • 3 answers
Posted 27 Jun 2017 • 0 answers